Ardelyx (ARDX)
NASDAQ:ARDX
Want to see ARDX full AI Analyst Report?
Earnings Data
Report Date
Aug 06, 2026After Close (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
-0.04Last Year’s EPS
-0.08Same Quarter Last Year
Strong Buy
Based on 5 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call presented multiple strong operational and commercial achievements — notably robust Ibsrela growth (58% YoY), solid product revenue expansion (+38% total product revenue), active pipeline advancement (EXCEL Phase 3 initiated with rapid site activation), improved net loss versus prior year, and strengthened financial optionality via debt refinancing and $238M in cash. Headwinds include elevated and growing OpEx tied to commercialization and Phase 3 activity, GAAP reporting complexity for Exposa due to prior‑year adjustments, Q1 seasonality and storm‑related disruptions, and near‑term gross‑to‑net pressure. On balance the company reiterated mid‑ and long‑term revenue targets and appears confident in execution, though profitability and competitive risk remain items to monitor.Company Guidance
Strong Q1 Revenue Growth
Total product revenues of $93.4M in Q1 2026, up 38% year-over-year from $67.8M, driven primarily by Ibsrela demand.
Ibsrela Momentum and Guidance
Ibsrela Q1 revenue of $70.1M, up 58% YoY. Company reiterated 2026 Ibsrela guidance of $410M–$430M (50%–57% YoY growth) and long-term target of at least $1B in annual revenue by 2029 (~38% CAGR).
Exposa Underlying Growth and Long-Term Target Reiterated
Exposa reported $23.3M in Q1 revenues (as-reported roughly flat YoY), but underlying paid prescriptions grew ~19% YoY after adjusting for a $3.8M favorable return reserve in Q1 2025. Company reiterated long-term Exposa target of $750M and 2026 guidance of $110M–$120M.
Pipeline Progress — EXCEL Phase 3 and Pediatric Program
Initiated EXCEL Phase 3 trial of Ibsrela in CIC; all pre-identified sites initiated in under four months and enrollment is on track to complete by year-end with topline data expected in 2027. Ongoing pediatric studies may support label expansion and could yield an additional six months of exclusivity via SNDA; Orange Book-listed 2099 patent added for commercial formulations.
Next-generation Program Advancing
Next‑generation NHE3 inhibitor (531) progressing through IND‑enabling studies, positioning potential expansion into additional therapeutic areas.
Commercial Execution and Access Initiatives Driving Pull‑Through
Commercial initiatives (Ibsrela Pharmacy Network, increased field reimbursement managers) are improving fulfillment and refill behavior — specialty pharmacy channel is ~30% of mix and the network reportedly yields higher fill rates and on average an additional refill per year.
Improved Losses and Financial Position; Debt Refinancing
Net loss narrowed to $37.6M (−$0.15/share) vs $41.1M (−$0.17) prior year. Cash, cash equivalents and short‑term investments of $238.1M. Refinance with SLR extended loan maturity/interest-only period, lowered cost of capital and preserves $100M available drawdown.
ARDX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
ARDX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Apr 30, 2026 | $6.33 | $6.88 | +8.69% |
Feb 19, 2026 | $6.74 | $5.73 | -14.99% |
Oct 30, 2025 | $5.01 | $6.06 | +20.96% |
Aug 04, 2025 | $4.39 | $5.13 | +16.86% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Ardelyx (ARDX) report earnings?
Ardelyx (ARDX) is schdueled to report earning on Aug 06, 2026, After Close (Confirmed).
What is Ardelyx (ARDX) earnings time?
Ardelyx (ARDX) earnings time is at Aug 06, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ARDX EPS forecast?
ARDX EPS forecast for the fiscal quarter 2026 (Q2) is -0.04.
